Studies Underway

There are currently 18 studies underway that include TVCC clients, their families, and/or TVCC staff:

Psychosocial

• Engagement in the pediatric rehabilitation intervention process: Its nature, measurement, and role in the determination of outcomes
  Oct. 2017-Jun. 2024
• Health concerns of adolescents and adults with childhood onset physical disability
  Jun. 2018-Mar. 2023
• Increasing our knowledge of social and motor skills in children with Autism Spectrum Disorder to help better understand participation in social activities 
  Oct. 2018-May 2024
• Learning to listen: Evaluating the effectiveness of an educational intervention to enhance the clinical listening skills of graduate students in audiology and speech-language pathology
  Aug. 2019-Aug. 2024
• Fit & Function: Family perspective on fit between education interventions and functional needs for young children with neurodevelopmental disorders
  Jun. 2021-Apr. 2023
• Hearing aid personalization with adolescents: A virtual synchronous focus group study to explore end-user and clinician perspectives
  Mar. 2021-Aug. 2024
• Innovative language assessment for children with low motor and speech function: Engaging end users to understand the necessary conditions for implementing the C-BiLLT in Canada
  Jul. 2022-Aug. 2023
• Perceived impact of the learning to listen intervention on novice clinicians' Listening and Communication Skill Development-Short Title-ELICS Learning to Listen Study
  Jul. 2022-Jul. 2024
• Development of a listening skill simulation intervention for pediatric rehabilitation therapists
  Oct. 2022-Oct. 2024
• Developing a Measure of Resiliency-related Adaptive Self-Capacities for Rehabilitation Intervention
  Apr. 2023-Apr. 2024
• Family Culture and the Special Olympics Movement
  Aug. 2023-Apr. 2024

Drug

• Canadian Neuromuscular Disease Registry
  Jan. 2010-Dec. 2024
• A phase 3, randomized, double blind, sham-procedure controlled study to assess the clinical efficacy and safety of ISIS 396443 administered intrathecally in patients with later-onset spinal muscular atrophy
  Dec. 2014-Ongoing
• A two-part seamless, multi-center randomized, placebo-controlled, double-blind study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of Ro7034067 in type2 and 3 spinal muscular atrophy patients
  Dec. 2016-May 2024
• A randomized, double-blind study to evaluate the efficacy and safety to Tideglusib versus placebo for the treatment of children and adolescents with congenital myotonic dystrophy (AMO study)
  Feb. 2018-Mar. 2023
• A phase2, two-part multiple-ascending dose study of SRP-5051 for dose determination, then dose expansion, in patients with Duchenne Muscular Dystrophy amenable to Exon 51-skipping treatment
  Jun. 2019-Sept. 2024
• Escalating dose and randomized controlled study of Nusinersen (BIIB058) in participating with spinal muscular atrophy
  Apr. 2020-Sept. 2023
• A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study Assessing Safety, Tolerability, Pharmacodynamics, Efficacy, and Pharmacokinetics of DYNE-251 Administered to Participants with Duchenne Muscular Dystrophy Amenable to Exon 51
  Jan. 2023-Jan. 2024